PRESS RELEASE

Cortellis for Competitive Intelligence

Thomson Reuters has introduced Cortellis for Competitive Intelligence, a product that the company says brings the best of the pharmaceutical data sources owned by Thomson Reuters into a single, intuitive solution.

Designed with users’ needs in mind, Cortellis for Competitive Intelligence is a life sciences intelligence tool that delivers critical information when you need it most. From drug discovery data to patent reports, Cortellis for Competitive Intelligence can give users the confidence to make the best  decisions for their organisation, faster.

The company says Cortellis for Competitive Intelligence saves time and resources through:

  • Superior analytics – easy-to-use analytics and visualisations to quickly interrogate data;
  • Trusted content – extensive pharmaceutical content, collated by industry experts, combined with commentary from the Thomson Reuters global team of scientific editors;
  • An intuitive interface allowing users to find the exact data they want, faster, with advanced searching techniques; and
  • The ability to access Cortellis whenever and wherever users want, and the ability to easily share results with agile export and reporting tools.
Company: 
Feature

Gemma Church finds out how astronomers are using simulations to investigate the extremities of our universe

Feature

Turning data into scientific insight is not a straightforward matter, writes Sophia Ktori

Feature

The Leibniz Supercomputing Centre (LRZ) is driving the development of new energy-efficient practices for HPC, as Robert Roe discovers

Feature

William Payne investigates the growing trend of using modular HPC, built on industry standard hardware and software, to support users across a range of both existing and emerging application areas

Feature

Robert Roe looks at developments in crash testing simulation – including larger, more intricate simulations, the use of optimisation software, and the development of new methodologies through collaboration between ISVs, commercial companies, and research organisations